Efthymios Deliargyris
Direttore Tecnico/Scientifico/R&S presso CYTOSORBENTS CORPORATION
Patrimonio netto: 287 831 $ in data 30/06/2024
Posizioni attive di Efthymios Deliargyris
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CYTOSORBENTS CORPORATION | Direttore Tecnico/Scientifico/R&S | 01/05/2020 | - |
Storia della carriera di Efthymios Deliargyris
Precedenti posizioni note di Efthymios Deliargyris
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Direttore Tecnico/Scientifico/R&S | 01/08/2018 | 30/04/2020 |
| ATHENS MEDICAL C.S.A. | Corporate Officer/Principal | 01/01/2004 | 01/01/2010 |
| Wake Forest University | Corporate Officer/Principal | 01/01/2001 | 01/01/2004 |
Formazione di Efthymios Deliargyris
| National & Kapodistrian University of Athens | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
| Grecia | 3 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ATHENS MEDICAL C.S.A. | Health Services |
| CYTOSORBENTS CORPORATION | Health Technology |
| Aziende private | 1 |
|---|---|
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
